查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930053

自闭症谱系障碍治疗市场规模、占有率、成长及全球产业分析：按类型、应用和地区划分的洞察，以及2025年至2034年的预测

Autism Spectrum Disorder Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 166 Pages | 商品交期: 请询问到货日

价格

自闭症谱系障碍 (ASD) 治疗市场成长驱动因素

预计2025年全球自闭症谱系障碍 (ASD) 治疗市场规模将达到85.5亿美元，2026年将成长至92.1亿美元，到2034年将达到186.8亿美元，2026年至2034年的复合年增长率 (CAGR) 为9.23%。北美地区在2025年将以5.08%的市占率领先，这主要得益于盛行率的上升、公众意识的提高以及对沟通和行为疗法投入的增加。

自闭症谱系障碍 (ASD) 是一种复杂的神经发育障碍，其特征是持续的沟通和社交互动障碍，以及受限或重复的行为模式。市场成长的驱动因素包括 ASD 盛行率的不断上升，尤其是在儿童群体中，以及对有效治疗的持续未满足的需求。根据美国疾病管制与预防中心 (CDC) 2025 年 5 月发布的一份报告，美国大约每 31 名 8 岁儿童中就有 1 名将被诊断出患有 ASD，这凸显了对专业治疗护理服务日益增长的需求。

市场驱动因素

推动市场成长的关键因素包括 ASD 盛行率的上升、早产儿存活率的提高、晚育以及怀孕期间接触某些药物和毒素等环境风险因素。护理人员和医疗保健专业人员对 ASD 的认识不断提高，以及公共和私人保险对 ASD 覆盖的支持，正在促进治疗方法的普及，尤其是在北美地区。

市场限制因子

某些地区专科医疗资源有限、临床医生短缺以及漫长的候诊名单限制了市场成长。症状严重程度的差异、治疗反应的差异以及严格的药物审批监管流程进一步限制了市场扩张。一些地区缺乏核准药物，促使人们更加依赖沟通和行为疗法，但这些疗法并非人人都能获得。

市场机会

来自私募股权公司和医疗保健公司的投资正在创造巨大的成长机会。虽然自闭症谱系障碍治疗市场仍未充分满足，但应用行为分析 (ABA) 等疗法的有效性正在推动投资和扩张。例如，Tenex Capital Management 于 2024 年 6 月收购了 Behavioral Innovations，这表明该公司持续致力于整合分散的市场并提高服务效率。

市场趋势

新兴趋势包括引进新的介入和教育计画。这些疗法结合了行为疗法、心理疗法、教育疗法和药物疗法，旨在提高患者的独立性和生活品质。人工智慧和技术疗法也日益受到关注，它们利用机器学习、虚拟实境 (VR) 和扩增实境 (AR) 平台来提高诊断准确性、客製化干预措施并提升治疗效率。

细分市场分析

依治疗类型划分：沟通行为疗法在2026年占市场主导地位，市占率高达74.75%。这主要归功于其已被证实的有效性和较高的普及率，而药物疗法的应用范围则较为有限。应用行为分析 (ABA) 疗法仍然是主要的成长驱动力，其服务提供者正在全球扩展其特许经营模式。药物治疗，包括兴奋剂、选择性血清素再摄取抑制剂（SSRI）、抗精神病药物和安眠药，预计将随着製药公司加大研发投入而成长。

按类型划分：自闭症谱系障碍（ASD）细分市场预计将在2026年占50.14%的市场占有率，成为市场主导，这主要得益于其高患病率、政府项目以及应用行为分析（ABA）疗法服务的扩展。广泛性发展障碍（PDD）占第二大市场占有率，而亚斯伯格症和其他ASD亚型由于临床投入有限，预计成长速度将放缓。

区域展望

北美地区预计将在2025年以50.8亿美元的收入引领市场，其主导地位将得益于高患病率、不断扩大的治疗选择以及保险覆盖范围。预计到2026年，美国市场规模将达到51.1亿美元，主要得益于ABA疗法特许经营机构的推动，例如位于德克萨斯州奥斯汀的Success on the Spectrum。

到2025年，欧洲将占第二大市场占有率，预计到2026年，英国和德国的市场规模将分别达到2.1亿美元和3.7亿美元，这主要归功于自闭症谱系障碍（ASD）患病率的上升和新型药物疗法的出现。亚太地区预计将实现最高的成长率，预计到2026年，日本、中国和印度的市场规模将分别达到4.2亿美元、4亿美元和1.6亿美元。这一增长主要得益于政府措施、宣传活动以及诊断率的提高。另一方面，由于医疗保健服务体系和政府支持方面的限制，拉丁美洲以及中东和非洲地区的成长速度预计将较为缓慢。

本报告详细概述了自闭症谱系障碍治疗市场，包括市场驱动因素、限制因素、趋势、按治疗类型划分的市场细分、区域分析、竞争格局、行业趋势和经济成本考量。报告还重点关注监管框架、报销方案以及新型技术驱动疗法对市场趋势的影响。

市场扩张的驱动因素包括自闭症谱系障碍盛行率的上升、照顾者和医疗保健提供者意识的提高，以及对有效治疗（尤其是儿童治疗）的持续未满足的需求。沟通和行为疗法，特别是应用行为分析（ABA），因其已被证实的有效性和广泛的应用，在治疗领域中占主导地位。由于製药业研发投入的增加和新药临床试验的增多，药物疗法正在逐步发展。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家/地区自闭症盛行率（2025 年）
  • 主要产业趋势（併购、合作等）
  • 主要国家/地区监管框架
  • 主要国家/地区自闭症谱系障碍治疗的全球报销和经济负担
  • COVID-19 的影响市场
  • ABA 产业的特许经营模式
  • 从药物治疗过渡到行为疗法：聚焦 ABA 疗法

第五章 全球自闭症谱系障碍治疗市场分析、洞察与预测 (2021-2034)

  • 市场分析、洞察与预测 - 按治疗类型划分
    • 沟通与行为疗法
      • 应用行为分析 (ABA)
      • 言语疗法
      • 职业疗法
      • 其他
    • 药物疗法
      • 抗精神病药物
      • 选择性血清素再摄取抑制剂 (SSRI)
      • 兴奋剂
      • 安眠药
      • 其他
    • 市场分析、洞察与预测 - 按类型划分
      • 自闭症谱系障碍
      • 亚斯伯格症
      • 广泛性发展障碍
      • 其他
    • 市场分析、洞察与预测 - 按地区划分
      • 北美
      • 欧洲
      • 亚太地区
      • 拉丁美洲
      • 中东和非洲

第六章：北美自闭症谱系障碍治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲自闭症谱系障碍治疗市场分析、洞察与预测（2021-2034）

  • 依国家/地区
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚半岛
    • 欧洲其他地区

第八章：亚太地区自闭症谱系障碍治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲自闭症谱系障碍治疗市场分析、洞察与预测（2021-2034）

  • 依国家/地区
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章 中东与非洲自闭症谱系障碍治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会 (GCC)
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2025）
  • 公司简介
    • Hopebridge, LLC.
    • 自闭症及相关障碍中心
    • 大冢控股株式会社
    • 辉瑞公司
    • 行为创新公司
    • 应用行为顾问公司
    • BlueSprig
    • 礼来公司
    • 成功谱系
    • 阿斯特捷利康
    • 强生服务公司
Product Code: FBI108573

Growth Factors of autism spectrum disorder (ASD) treatment Market

The global autism spectrum disorder (ASD) treatment market was valued at USD 8.55 billion in 2025 and is projected to grow to USD 9.21 billion in 2026, reaching USD 18.68 billion by 2034, representing a CAGR of 9.23% from 2026 to 2034. North America dominated the market in 2025 with a 5.08% share, driven by rising prevalence, growing awareness, and increasing investment in communication and behavioral therapies.

ASD is a complex neurodevelopmental disorder characterized by persistent deficits in communication and social interaction, alongside restricted or repetitive patterns of behavior. Market growth is being fueled by the rising prevalence of ASD, particularly in children, and the persistent unmet need for effective therapies. According to the CDC in May 2025, approximately 1 in 31 children aged 8 in the U.S. are diagnosed with ASD, highlighting the increasing demand for specialized treatment and care services.

Market Drivers

Key factors driving market growth include rising prevalence of ASD, higher survival rates of premature babies, late-age pregnancies, and exposure to environmental risk factors such as certain drugs or toxins during pregnancy. Increased awareness among caregivers and healthcare providers, along with private and public support for insurance coverage, is boosting the adoption of treatment options, particularly in North America.

Market Restraints

Limited access to specialized care in certain regions, clinician shortages, and long waitlists restrict market growth. Variability in symptom severity, diverse responses to therapies, and stringent regulatory pathways for drug approvals further constrain market expansion. The lack of approved drugs in some regions emphasizes the reliance on communication and behavioral therapies, which may not be uniformly accessible.

Market Opportunities

Investments from private equity firms and healthcare companies are creating significant growth opportunities. ASD treatment remains an underserved market, but the effectiveness of therapies such as Applied Behavior Analysis (ABA) has attracted investment and expansion. For instance, in June 2024, Tenex Capital Management acquired Behavioral Innovations, demonstrating the ongoing interest in consolidating fragmented markets and increasing service efficiency.

Market Trends

Emerging trends include the introduction of novel interventional and educational programs, combining behavioral, psychological, educational, and pharmacological therapies to enhance patient independence and quality of life. AI and technology-based therapies are gaining traction, including machine learning, virtual reality, and augmented reality platforms to improve diagnosis, customize interventions, and enhance treatment efficiency.

Segmentation Analysis

By Treatment Type: Communication and behavioral therapies dominated the market in 2026 with a 74.75% share, due to their proven effectiveness and higher adoption compared to limited drug therapies. ABA therapy remains a key driver of growth, with providers expanding franchise models globally. Drug therapies, including stimulants, SSRIs, antipsychotics, and sleep medications, are expected to grow as pharmaceutical companies intensify R&D efforts.

By Type: The autistic disorder segment led the market in 2026 with a 50.14% share, supported by high prevalence, government programs, and expansion of ABA therapy services. Pervasive developmental disorder (PDD) holds the second-largest share, while Asperger syndrome and other ASD types are projected to grow at slower rates due to limited clinical initiatives.

Regional Outlook

North America led the market in 2025 with USD 5.08 billion in revenue, maintaining dominance due to high prevalence, expanded therapy options, and insurance coverage support. The U.S. market is projected to reach USD 5.11 billion by 2026, bolstered by ABA therapy franchises such as Success on the Spectrum in Austin, Texas.

Europe held the second-largest share in 2025, with the UK and Germany projected to reach USD 0.21 billion and USD 0.37 billion by 2026, driven by rising ASD prevalence and new drug therapies. Asia Pacific is expected to grow at the fastest rate, with Japan, China, and India projected to reach USD 0.42 billion, USD 0.4 billion, and USD 0.16 billion respectively by 2026, supported by government policies, awareness programs, and increased diagnosis. Latin America and the Middle East & Africa are growing at a slower pace due to limited healthcare provisions and government support.

Competitive Landscape

The ASD treatment market is highly fragmented, with communication & behavioral therapy providers such as BlueSprig, Action Behavioral Centers (ABC), ACES ABA, Centria Autism, Hopebridge, and SUCCESS ON THE SPECTRUM dominating the segment. Leading pharmaceutical companies in drug therapies include Otsuka Pharmaceuticals, AstraZeneca, Pfizer, Eli Lilly, and Johnson & Johnson. Key strategies involve expansion, acquisitions, collaborations, and R&D initiatives, such as BlueSprig's acquisition of Trumpet Behavioral Health in October 2023 and ongoing clinical trials for novel ASD drugs.

Report Coverage

The report offers a detailed overview of the ASD treatment market, including market drivers, restraints, trends, segmentation by type and therapy, regional analysis, competitive landscape, industry developments, and economic cost considerations. Additionally, it highlights regulatory frameworks, reimbursement scenarios, and the impact of emerging technology-driven therapies on the market trajectory.

Conclusion

The global autism spectrum disorder treatment market is poised for strong growth, with a valuation of USD 8.55 billion in 2025, projected to reach USD 9.21 billion in 2026, and forecasted to hit USD 18.68 billion by 2034, representing a CAGR of 9.23% during the period 2026-2034. North America remains the largest market, supported by high prevalence rates, widespread adoption of communication and behavioral therapies, insurance coverage, and ongoing investments in innovative treatment solutions.

Market expansion is driven by the rising prevalence of ASD, increased awareness among caregivers and healthcare providers, and persistent unmet needs for effective therapies, particularly in children. Communication and behavioral therapies, especially Applied Behavior Analysis (ABA), dominate the treatment landscape due to their proven effectiveness and widespread adoption. Drug therapies are gradually expanding with growing pharmaceutical R&D and clinical trials for novel medications.

Segmentation By Treatment Type

  • Communication & Behavioral Therapies
    • Applied Behavior Analysis (ABA)
    • Speech & Language Therapy
    • Occupational Therapy
    • Others
  • Drug Therapies
    • Antipsychotic Drugs
    • SSRIs/Antidepressants
    • Stimulants
    • Sleep Medications
    • Others

By Type

  • Autistic Disorder
  • Asperger Syndrome
  • Pervasive Developmental Disorder (PDD)
  • Others

By Geography

  • North America (By Treatment Type, Type, and Country)
  • U.S.
  • Canada
  • Europe (By Treatment Type, Type, and Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
  • Asia Pacific (By Treatment Type, Type, and Country/Sub-Region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
  • Latin America (By Treatment Type, Type, and Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
  • The Middle East & Africa (By Treatment Type, Type, and Country/Sub-Region)
  • GCC Countries
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Autism, By Key Countries, 2025
  • 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.3. Regolatory Framework by Key Countries/Regions
  • 4.4. Global Reimbursement Scenario and Economic Cost Burden for the Treatment of Autism Spectrum Disorder by Key Countries/Region
  • 4.5. Impact of COVID-19 on the Market
  • 4.6. A Franchise Model in ABA Industry
  • 4.7. Shift from Pharmacological Interventions to Behavioral Therapies: Focus on ABA Therapy

5. Global Autism Spectrum Disorder Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Treatment Type
    • 5.1.1. Communication & Behavioral Therapies
      • 5.1.1.1. Applied Behavior Analysis (ABA)
      • 5.1.1.2. Speech & Language Therapy
      • 5.1.1.3. Occupational Therapy
      • 5.1.1.4. Others
    • 5.1.2. Drug Therapy
      • 5.1.2.1. Antipsychotic Drugs
      • 5.1.2.2. SSRIS
      • 5.1.2.3. Stimolants
      • 5.1.2.4. Sleep Medications
      • 5.1.2.5. Others
    • 5.1.3. Market Analysis, Insights and Forecast - By Type
      • 5.1.3.1. Autistic Disorder
      • 5.1.3.2. Asperger Syndrome
      • 5.1.3.3. Pervasive Developmental Disorder
      • 5.1.3.4. Others
    • 5.1.4. Market Analysis, Insights and Forecast - By Region
      • 5.1.4.1. North America
      • 5.1.4.2. Europe
      • 5.1.4.3. Asia Pacific
      • 5.1.4.4. Latin America
      • 5.1.4.5. Middle East & Africa

6. North America Autism Spectrum Disorder Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Treatment Type
    • 6.1.1. Communication & Behavioral Therapies
      • 6.1.1.1. Applied Behavior Analysis (ABA)
      • 6.1.1.2. Speech & Language Therapy
      • 6.1.1.3. Occupational Therapy
      • 6.1.1.4. Others
    • 6.1.2. Drug Therapy
      • 6.1.2.1. Antipsychotic Drugs
      • 6.1.2.2. SSRIS
      • 6.1.2.3. Stimolants
      • 6.1.2.4. Sleep Medications
      • 6.1.2.5. Others
    • 6.1.3. Market Analysis, Insights and Forecast - By Type
      • 6.1.3.1. Autistic Disorder
      • 6.1.3.2. Asperger Syndrome
      • 6.1.3.3. Pervasive Developmental Disorder
      • 6.1.3.4. Others
    • 6.1.4. Market Analysis, Insights and Forecast - By Country
      • 6.1.4.1. U.S.
      • 6.1.4.2. Canada

7. Europe Autism Spectrum Disorder Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Treatment Type
    • 7.1.1. Communication & Behavioral Therapies
      • 7.1.1.1. Applied Behavior Analysis (ABA)
      • 7.1.1.2. Speech & Language Therapy
      • 7.1.1.3. Occupational Therapy
      • 7.1.1.4. Others
    • 7.1.2. Drug Therapy
      • 7.1.2.1. Antipsychotic Drugs
      • 7.1.2.2. SSRIS
      • 7.1.2.3. Stimolants
      • 7.1.2.4. Sleep Medications
      • 7.1.2.5. Others
    • 7.1.3. Market Analysis, Insights and Forecast - By Type
      • 7.1.3.1. Autistic Disorder
      • 7.1.3.2. Asperger Syndrome
      • 7.1.3.3. Pervasive Developmental Disorder
      • 7.1.3.4. Others
    • 7.1.4. Market Analysis, Insights and Forecast - By Country/Sub-region
      • 7.1.4.1. U.K.
      • 7.1.4.2. Germany
      • 7.1.4.3. France
      • 7.1.4.4. Spain
      • 7.1.4.5. Italy
      • 7.1.4.6. Scandinavia
      • 7.1.4.7. Rest of Europe

8. Asia Pacific Autism Spectrum Disorder Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Treatment Type
    • 8.1.1. Communication & Behavioral Therapies
      • 8.1.1.1. Applied Behavior Analysis (ABA)
      • 8.1.1.2. Speech & Language Therapy
      • 8.1.1.3. Occupational Therapy
      • 8.1.1.4. Others
    • 8.1.2. Drug Therapy
      • 8.1.2.1. Antipsychotic Drugs
      • 8.1.2.2. SSRIS
      • 8.1.2.3. Stimolants
      • 8.1.2.4. Sleep Medications
      • 8.1.2.5. Others
    • 8.1.3. Market Analysis, Insights and Forecast - By Type
      • 8.1.3.1. Autistic Disorder
      • 8.1.3.2. Asperger Syndrome
      • 8.1.3.3. Pervasive Developmental Disorder
      • 8.1.3.4. Others
    • 8.1.4. Market Analysis, Insights and Forecast - By Country/Sub-region
      • 8.1.4.1. Japan
      • 8.1.4.2. China
      • 8.1.4.3. India
      • 8.1.4.4. Australia
      • 8.1.4.5. Southeast Asia
      • 8.1.4.6. Rest of Asia Pacific

9. Latin America Autism Spectrum Disorder Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Treatment Type
    • 9.1.1. Communication & Behavioral Therapies
      • 9.1.1.1. Applied Behavior Analysis (ABA)
      • 9.1.1.2. Speech & Language Therapy
      • 9.1.1.3. Occupational Therapy
      • 9.1.1.4. Others
    • 9.1.2. Drug Therapy
      • 9.1.2.1. Antipsychotic Drugs
      • 9.1.2.2. SSRIS
      • 9.1.2.3. Stimolants
      • 9.1.2.4. Sleep Medications
      • 9.1.2.5. Others
    • 9.1.3. Market Analysis, Insights and Forecast - By Type
      • 9.1.3.1. Autistic Disorder
      • 9.1.3.2. Asperger Syndrome
      • 9.1.3.3. Pervasive Developmental Disorder
      • 9.1.3.4. Others
    • 9.1.4. Market Analysis, Insights and Forecast - By Country/Sub-region
      • 9.1.4.1. Brazil
      • 9.1.4.2. Mexico
      • 9.1.4.3. Rest of Latin America

10. Middle East & Africa Autism Spectrum Disorder Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Treatment Type
    • 10.1.1. Communication & Behavioral Therapies
      • 10.1.1.1. Applied Behavior Analysis (ABA)
      • 10.1.1.2. Speech & Language Therapy
      • 10.1.1.3. Occupational Therapy
      • 10.1.1.4. Others
    • 10.1.2. Drug Therapy
      • 10.1.2.1. Antipsychotic Drugs
      • 10.1.2.2. SSRIS
      • 10.1.2.3. Stimolants
      • 10.1.2.4. Sleep Medications
      • 10.1.2.5. Others
    • 10.1.3. Market Analysis, Insights and Forecast - By Type
      • 10.1.3.1. Autistic Disorder
      • 10.1.3.2. Asperger Syndrome
      • 10.1.3.3. Pervasive Developmental Disorder
      • 10.1.3.4. Others
    • 10.1.4. Market Analysis, Insights and Forecast - By Country/Sub-region
      • 10.1.4.1. GCC Countries
      • 10.1.4.2. South Africa
      • 10.1.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Hopebridge, LLC.
      • 11.2.1.1. Overview
      • 11.2.1.2. Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Center for Autism and Related Disorders
      • 11.2.2.1. Overview
      • 11.2.2.2. Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Otsuka Holdings Co., Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Pfizer Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Behavioral Innovations
      • 11.2.5.1. Overview
      • 11.2.5.2. Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Applied Behavior Consoltants, Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. BlueSprig
      • 11.2.7.1. Overview
      • 11.2.7.2. Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Eli Lilly and Company
      • 11.2.8.1. Overview
      • 11.2.8.2. Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. SUCCESS ON THE SPECTRUM
      • 11.2.9.1. Overview
      • 11.2.9.2. Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. AstraZeneca
      • 11.2.10.1. Overview
      • 11.2.10.2. Services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Johnson & Johnson Services, Inc.
      • 11.2.11.1. Overview
      • 11.2.11.2. Services
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Treatment Type, 2021-2034
  • Table 2: Global Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Communication & Behavioral Therapies, 2021-2034
  • Table 3: Global Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Drug Therapies, 2021-2034
  • Table 4: Global Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 5: Global Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Treatment Type, 2021-2034
  • Table 7: North America Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Communication & Behavioral Therapies, 2021-2034
  • Table 8: North America Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Drug Therapies, 2021-2034
  • Table 9: North America Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 10: North America Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Treatment Type, 2021-2034
  • Table 12: Europe Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Communication & Behavioral Therapies, 2021-2034
  • Table 13: Europe Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Drug Therapies, 2021-2034
  • Table 14: Europe Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 15: Europe Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Treatment Type, 2021-2034
  • Table 17: Asia Pacific Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Communication & Behavioral Therapies, 2021-2034
  • Table 18: Asia Pacific Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Drug Therapies, 2021-2034
  • Table 19: Asia Pacific Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 20: Asia Pacific Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Treatment Type, 2021-2034
  • Table 22: Latin America Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Communication & Behavioral Therapies, 2021-2034
  • Table 23: Latin America Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Drug Therapies, 2021-2034
  • Table 24: Latin America Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 25: Latin America Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Treatment Type, 2021-2034
  • Table 27: Middle East & Africa Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Communication & Behavioral Therapies, 2021-2034
  • Table 28: Middle East & Africa Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Drug Therapies, 2021-2034
  • Table 29: Middle East & Africa Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 30: Middle East & Africa Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Autism Spectrum Disorder Treatment Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Autism Spectrum Disorder Treatment Market Value Share (%), By Treatment Type, 2025 & 2034
  • Figure 3: Global Autism Spectrum Disorder Treatment Market Value Share (%), By Type, 2025 & 2034
  • Figure 4: Global Autism Spectrum Disorder Treatment Market Value (USD billion), by Region, 2025 & 2034
  • Figure 5: North America Autism Spectrum Disorder Treatment Market Value (USD billion), By Treatment Type, 2025 & 2034
  • Figure 6: North America Autism Spectrum Disorder Treatment Market Value Share (%), By Treatment Type, 2025
  • Figure 7: North America Autism Spectrum Disorder Treatment Market Value (USD billion), By Type, 2025 & 2034
  • Figure 8: North America Autism Spectrum Disorder Treatment Market Value Share (%), By Type, 2025
  • Figure 9: North America Autism Spectrum Disorder Treatment Market Value (USD billion), By Country, 2025 & 2034
  • Figure 10: North America Autism Spectrum Disorder Treatment Market Value Share (%), By Country, 2025
  • Figure 11: Europe Autism Spectrum Disorder Treatment Market Value (USD billion), By Treatment Type, 2025 & 2034
  • Figure 12: Europe Autism Spectrum Disorder Treatment Market Value Share (%), By Treatment Type, 2025
  • Figure 13: Europe Autism Spectrum Disorder Treatment Market Value (USD billion), By Type, 2025 & 2034
  • Figure 14: Europe Autism Spectrum Disorder Treatment Market Value Share (%), By Type, 2025
  • Figure 15: Europe Autism Spectrum Disorder Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 16: Europe Autism Spectrum Disorder Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 17: Asia Pacific Autism Spectrum Disorder Treatment Market Value (USD billion), By Treatment Type, 2025 & 2034
  • Figure 18: Asia Pacific Autism Spectrum Disorder Treatment Market Value Share (%), By Treatment Type, 2025
  • Figure 19: Asia Pacific Autism Spectrum Disorder Treatment Market Value (USD billion), By Type, 2025 & 2034
  • Figure 20: Asia Pacific Autism Spectrum Disorder Treatment Market Value Share (%), By Type, 2025
  • Figure 21: Asia Pacific Autism Spectrum Disorder Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 22: Asia Pacific Autism Spectrum Disorder Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 23: Latin America Autism Spectrum Disorder Treatment Market Value (USD billion), By Treatment Type, 2025 & 2034
  • Figure 24: Latin America Autism Spectrum Disorder Treatment Market Value Share (%), By Treatment Type, 2025
  • Figure 25: Latin America Autism Spectrum Disorder Treatment Market Value (USD billion), By Type, 2025 & 2034
  • Figure 26: Latin America Autism Spectrum Disorder Treatment Market Value Share (%), By Type, 2025
  • Figure 27: Latin America Autism Spectrum Disorder Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 28: Latin America Autism Spectrum Disorder Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 29: Middle East & Africa Autism Spectrum Disorder Treatment Market Value (USD billion), By Treatment Type, 2025 & 2034
  • Figure 30: Middle East & Africa Autism Spectrum Disorder Treatment Market Value Share (%), By Treatment Type, 2025
  • Figure 31: Middle East & Africa Autism Spectrum Disorder Treatment Market Value (USD billion), By Type, 2025 & 2034
  • Figure 32: Middle East & Africa Autism Spectrum Disorder Treatment Market Value Share (%), By Type, 2025
  • Figure 33: Middle East & Africa Autism Spectrum Disorder Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 34: Middle East & Africa Autism Spectrum Disorder Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 35: Global Autism Spectrum Disorder Treatment Market Share (%), By Company, 2025